COVID-19

For more information on COVID-19 and the visitor restrictions in place at Capital Health, click here.
For information on our advanced safety measures for receiving care during the COVID-19 pandemic, click here.

Can we help you find something?

Can we help you find something?

Clinical Trials

Our Clinical Cancer Trials

Capital Health Cancer Center participates in many National Cancer Institute (NCI), university and pharmaceutical phase II and III clinical trials. Some studies lead to the discovery of new methods to detect and diagnose cancer, while others focus on innovative treatments before they become widely available.

Clinical trials offer patients the very latest in cancer care while giving physicians and researchers the opportunity to study the effectiveness of the treatment. Participation is entirely voluntary.

Our experienced oncologists and research nurses carefully review study criteria, potential benefits, risks, and other considerations with eligible patients for enrollment into a clinical study. Once enrolled, our Clinical Research Department staff carefully monitors patients throughout the research trial and is available to answer questions.

The National Cancer Institute has a brochure Taking Part in Cancer Treatment Research Studies to help you understand the details of clinical trials.

To learn more about our ongoing trials for cancer treatment and prevention, please contact Tina Bergner, RN, BSN, OCN, oncology clinical research coordinator, at 609-537-7042 or e-mail her at [email protected] for more information.

Active clinical trials currently being offered:

Brain Studies

3D-PREDICT REGISTRY: 3D Prediction of patient-specific response using ex vivo interrogation of live cells from tumors

Observation or radiation therapy in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery

Molecular and biochemical characterization of malignant and metastatic brain tumors

  • Study Information: NCT N/A
  • Sponsor: Capital Health System, Inc. in collaboration with Princeton University and Rutgers University
  • Principal Investigator: Navid Redjal, MD, FAAN, Neurosurgeon
  • Contact: Dr. Neena Shetty, Clinical Research Coordinator at [email protected] or 609-394-4024

Genomically-guided treatment trial in brain metastasis

Assessing quality of life in adult neuro-oncology patients after Cyberknife or WBRT (Whole Brain Radiation Therapy), a prospective registry

  • Study Information: NCT N/A
  • Sponsor: Capital Health System, Inc.
  • Principal Investigator: Navid Redjal, MD, FAAN, Neurosurgeon
  • Contact: Dr. Neena Shetty, Clinical Research Coordinator at [email protected] or 609-394-4024

The use of the ketogenic diet as an adjuvant to treatment of glioblastome multiforme

  • Study Information: NCT N/A
  • Sponsor: Capital Health System, Inc.
  • Principal Investigator: Navid Redjal, MD, FAAN, Neurosurgeon
  • Contact: Dr. Neena Shetty, Clinical Research Coordinator at [email protected] or 609-394-4024
Breast Studies

Randomized, phase III trial evaluating the role of weight loss in adjuvant treatment of overweight women with early breast cancer (BWEL)

Liver and Pancreas Studies

Registry to evaluate effectiveness and safety of the Nanoknife system for the ablation of stage 3 pancreatic cancer – DIRECT

Circulating Biomarkers and Cancer

  • Study Information: NCT N/A
  • Sponsor: Capital Health System, Inc. in collaboration with the Blumberg Institute, PA
  • Principal Investigator: Cataldo Doria, MD, PhD, MBA, FCAS, Surgeon, Medical Director Cancer Center
  • Contact: Tina Bergner, RN, BSN, OCN, Clinical Research Coordinator at [email protected] or 609-394-7042
Gynecology Studies

A non-randomized prospective clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers

Lung Studies

A randomized phase III trial of induction/consolidation Atezolizumab + SBRT Versus SBRT alone in high risk, early stage NSCLC

Other Organs

NCI-MATCH: Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors, lymphomas, or multiple myeloma

Cancer Tissue Biorepository

  • Study Information: NCT N/A
  • Sponsor: Capital Health System, Inc.
  • Principal Investigator: Krister Jones, MD, Pathologist
  • Contact: Tina Bergner, RN, BSN, OCN, Clinical Research Coordinator at [email protected] or 609-394-7042

Other resources:

Capital Health Becomes Region’s First Center of Excellence in Robotic Surgery

In August, Capital Health Medical Center- Hopewell was designated a Center of Excellence in Robotic Surgery by Surgical Review Corporation (SRC). The Center of Excellence accreditation distinguishes Capital Health as having met rigorous, internationally recognized standards in providing the safest, highest quality of care and surgical capabilities.

 

Capital Health earns LGBTQ Health Care Equality Leader Designation in Human Rights Campaign Foundation’s Healthcare Equality Index

“Capital Health’s designation as an LGBTQ Health Care Equality Leader affirms our commitment to diversity, equity and inclusion in the care we deliver to our patients, our relationship with the communities we serve and the support we provide for our employees.” -- Dr. Eric Schwartz, vice president of Community Health and Transformation and executive director of Capital Health’s Institute for Urban Care

Capital Health Moves Primary Care Office to New Location in Yardley

Capital Health Primary Care – Langhorne, part of Capital Health Medical Group and a trusted provider of primary care for children and adults in Bucks County, Pennsylvania, has moved to a new location at 1690 Big Oak Road in Yardley. As a result of the move, the name of the practice has changed to Capital Health Primary Care – Yardley.

View All News
View All Events